Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566585 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
A Phase 1 study, sponsored by BlueSphere Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT07566585: Recruiting Phase 1 study, sponsored by BlueSphere Bio.
NCT07566585 is a Phase 1 study that is actively recruiting participants, run by BlueSphere Bio. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07566585, a Phase 1 study, is actively recruiting participants, sponsored by BlueSphere Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
Primary Outcome
Incidence of dose-limiting toxicity, frequency and severity of adverse events (AEs) and serious AEs (SAEs)
Interventions
- DRUG SOC+ BSB-2002
- DRUG SOC+BSB-2002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT07566585 shows while recruiting
NCT07566585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which SOC+ BSB-2002 is the first listed.
NCT07566585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07566585 about?
NCT07566585 is a clinical study titled "Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation". The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
What is the current status of trial NCT07566585?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2026-04-21. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07566585?
The interventions under investigation include: SOC+ BSB-2002 (DRUG), SOC+BSB-2002 (DRUG).
Who is sponsoring clinical trial NCT07566585?
This trial is sponsored by BlueSphere Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07566585's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI